SANDOZ CANAGLIFLOZIN DIN 02510421
Health Canada record
| Active ingredient(s) | CANAGLIFLOZIN 100 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A10BK02 CANAGLIFLOZIN |
| Original market date | |
| Current status date | 02-Jan-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sandoz Canada Incorporated — licence 101370, currently licensed, last inspection rating C (2025-02-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CANAGLIFLOZIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02544520 | AG-CANAGLIFLOZIN | ANGITA PHARMA INC. | Tablet | CANAGLIFLOZIN 300 MG | Approved |
| 02544512 | AG-CANAGLIFLOZIN | ANGITA PHARMA INC. | Tablet | CANAGLIFLOZIN 100 MG | Approved |
| 02564556 | APO-CANAGLIFLOZIN | APOTEX INC | Tablet | CANAGLIFLOZIN 100 MG | Marketed |
| 02564564 | APO-CANAGLIFLOZIN | APOTEX INC | Tablet | CANAGLIFLOZIN 300 MG | Marketed |
| 02510375 | AURO-CANAGLIFLOZIN | AURO PHARMA INC | Tablet | CANAGLIFLOZIN 300 MG | Marketed |
| 02510367 | AURO-CANAGLIFLOZIN | AURO PHARMA INC | Tablet | CANAGLIFLOZIN 100 MG | Marketed |
| 02455420 | INVOKAMET | JANSSEN INC | Tablet | CANAGLIFLOZIN 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02455455 | INVOKAMET | JANSSEN INC | Tablet | CANAGLIFLOZIN 150 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02455404 | INVOKAMET | JANSSEN INC | Tablet | CANAGLIFLOZIN 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Marketed |
| 02425483 | INVOKANA | JANSSEN INC | Tablet | CANAGLIFLOZIN 100 MG | Marketed |
| 02425491 | INVOKANA | JANSSEN INC | Tablet | CANAGLIFLOZIN 300 MG | Marketed |
| 02543494 | JAMP CANAGLIFLOZIN | JAMP PHARMA CORPORATION | Tablet | CANAGLIFLOZIN 300 MG | Marketed |
| 02543486 | JAMP CANAGLIFLOZIN | JAMP PHARMA CORPORATION | Tablet | CANAGLIFLOZIN 100 MG | Marketed |
| 02510448 | SANDOZ CANAGLIFLOZIN | SANDOZ CANADA INCORPORATED | Tablet | CANAGLIFLOZIN 300 MG | Approved |
| 02455412 | INVOKAMET | JANSSEN INC | Tablet | CANAGLIFLOZIN 50 MG; METFORMIN HYDROCHLORIDE 850 MG | Cancelled Post Market |
| 02455447 | INVOKAMET | JANSSEN INC | Tablet | CANAGLIFLOZIN 150 MG; METFORMIN HYDROCHLORIDE 850 MG | Cancelled Post Market |
| 02455439 | INVOKAMET | JANSSEN INC | Tablet | CANAGLIFLOZIN 150 MG; METFORMIN HYDROCHLORIDE 500 MG | Cancelled Post Market |
| 02477394 | INVOKAMET XR | JANSSEN INC | Tablet (Extended-Release) | CANAGLIFLOZIN 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Cancelled Pre Market |
| 02477424 | INVOKAMET XR | JANSSEN INC | Tablet (Extended-Release) | CANAGLIFLOZIN 150 MG; METFORMIN HYDROCHLORIDE 1000 MG | Cancelled Pre Market |
| 02477408 | INVOKAMET XR | JANSSEN INC | Tablet (Extended-Release) | CANAGLIFLOZIN 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Cancelled Pre Market |
| 02477416 | INVOKAMET XR | JANSSEN INC | Tablet (Extended-Release) | CANAGLIFLOZIN 150 MG; METFORMIN HYDROCHLORIDE 500 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36677 | 2026-01-02 | Abbreviated New Drug Submission (ANDS) |
International API supply for CANAGLIFLOZIN
25 active FDA Drug Master Files.
Request a quote for SANDOZ CANAGLIFLOZIN